No immediate stock-moving catalyst; traders should monitor for topline Phase 2 data in H2 2026. Phase 1 hsCRP reductions were strong, but Phase 2 proof-of-concept is still highly binary and carries clinical risk. Given poor historical calibration on BIOA (T+20 avg -12.9%, 13% win rate), conservative positioning is warranted until actual data readout.
Price Chart
Executive Summary
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026 — a routine operational milestone with no financial or efficacy data disclosed.
Key Facts
- First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
- Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
- Primary endpoint: percent change from baseline in hsCRP
- Topline data anticipated in second half of 2026
- Phase 1 data previously showed 86% median hsCRP reduction at 60 mg and 120 mg doses
Financial Impact
No financial data in release; $882M market cap, clinical-stage company with no revenue
Risk Factors
- Phase 2 may fail to replicate Phase 1 hsCRP reductions or show clinical benefit
- Competition from other NLRP3 inhibitors and anti-inflammatory cardiovascular therapies
- No approved products or revenue; capital needs for further development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312476 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 15w ago | Press Release | $20.49 $8.65 | ▼ −57.78% | ▼ −58.78% | $6.72 (−67.20%) |
May 8, 2026 21w ago | 8-K | $17.99 $11.20 | ▼ −37.74% | ▼ −42.58% | $6.72 (−62.65%) |
Apr 21, 2026 23w ago | DEFA14A | $18.36 $22.81 | ▲ +24.24% | ▲ +19.46% | $6.72 (−63.40%) |
Apr 21, 2026 23w ago | Press Release | $19.61 $22.16 | ▲ +13.00% | ▲ +6.10% | $6.72 (−65.73%) |
Apr 1, 2026 26w ago | 144 | $17.73 $24.95 | ▲ +40.72% | ▲ +27.34% | $6.72 (−62.10%) |
Mar 24, 2026 27w ago | Press Release | $16.11 $20.77 | ▲ +28.93% | ▲ +14.60% | $6.72 (−58.29%) |
Mar 2, 2026 30w ago | Court Ruling | $21.71 $16.95 | ▼ −21.93% | ▼ −31.26% | $6.72 (−69.05%) |
Feb 28, 2026 30w ago | Institutional Cluster | $21.71 $16.20 | ▼ −25.38% | ▼ −34.71% | $6.72 (−69.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access